Tesofensine vs Semaglutide: Oral Monoamine vs GLP-1 Mechanisms Compared
Tesofensine blocks 3 monoamine transporters orally; semaglutide agonises the GLP-1 receptor. Compare mechanism, half-life, and Phase 2 vs Phase 3 evidence.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Tesofensine and semaglutide are studied as metabolic research compounds that reduce food intake through fundamentally different routes: tesofensine acts centrally as an orally administered triple monoamine reuptake inhibitor, while semaglutide is a subcutaneously or orally administered GLP-1 receptor agonist peptide. Researchers comparing non-incretin and incretin pathways frequently place these two side by side because they represent the clearest available contrast between central catecholaminergic appetite modulation and peripheral-to-central incretin receptor signalling.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Tesofensine is a small-molecule triple monoamine (dopamine, norepinephrine, serotonin) reuptake inhibitor investigated orally in Phase 2 obesity research, whereas semaglutide is a 31-amino-acid GLP-1 receptor agonist peptide with completed Phase 3 programmes and FDA approval. The two are not interchangeable in study design: they engage different receptor families, differ roughly 20-fold in molecular weight, and carry very different regulatory standings.
TL;DR:
- Tesofensine blocks the dopamine, norepinephrine and serotonin transporters; semaglutide agonises the GLP-1 receptor.
- Tesofensine is a small molecule (MW ~ 313 g/mol as the free base); semaglutide is an acylated peptide (MW ~ 4,113 g/mol).
- Semaglutide has Phase 3 obesity outcome data and regulatory approval; tesofensine's obesity programme stalled after Phase 2 and has no FDA or EMA approval.
- Both have long effective half-lives permitting infrequent administration, but for different structural reasons — slow transporter dissociation versus albumin-binding acylation.
- Non-incretin mechanisms remain an active research area precisely because they do not depend on GLP-1 receptor expression or incretin tolerance.
Tesofensine: mechanism and evidence base
Tesofensine (originally coded NS2330) is a phenyltropane-derived small molecule that inhibits the presynaptic reuptake of dopamine, norepinephrine and serotonin. It was first investigated as a candidate for neurodegenerative indications before appetite reduction was noted as a consistent secondary observation, which redirected later research toward metabolic endpoints. The compound's profile is detailed on the tesofensine library page.
The clearest structural account of how tesofensine engages its principal target comes from cryo-EM work on the dopamine transporter. Investigators resolved an ensemble of DAT structures bound to five distinct triple reuptake inhibitors and reported that "tesofensine and dasotraline stabilize DAT in an outward-facing conformation," in contrast to compounds that captured the inward-facing state (PMID 41392177). That conformational preference is mechanistically important: an outward-facing block prevents substrate translocation while leaving the transporter accessible from the extracellular side, which helps explain the compound's slow dissociation kinetics and long functional duration relative to its plasma exposure.
Published obesity research on tesofensine has been limited to Phase 2. The TIPO-1 study administered 0.25, 0.5 and 1.0 mg once daily orally over 24 weeks in adult participants and reported dose-dependent reductions in body weight relative to placebo, with monoaminergic adverse effects — elevated heart rate, blood pressure changes, dry mouth and sleep disturbance — emerging at the higher doses. No Phase 3 obesity programme has published results in the peer-reviewed literature, and the compound has not been approved by the FDA or the EMA for any indication. Regional approvals outside the United States and European Union have been reported but do not change its investigational status in US research contexts.
Semaglutide: mechanism and evidence base
Semaglutide is a 31-amino-acid analogue of human GLP-1 carrying an aminoisobutyric acid substitution at position 8 (which resists DPP-4 cleavage) and a C18 diacid fatty-acid chain attached via a γ-glutamyl and short polyethylene-glycol spacer to lysine 26. That acylation drives reversible albumin binding, which is the principal reason its half-life extends to roughly 165–184 hours rather than the minutes characteristic of native GLP-1. Full structural and pharmacological data appear on the semaglutide library page.
Mechanistically, semaglutide binds the class B G-protein-coupled GLP-1 receptor, activating Gαs, raising intracellular cAMP and driving PKA and Epac2 signalling. In pancreatic beta cells this potentiates glucose-dependent insulin secretion; in hypothalamic and hindbrain nuclei expressing the receptor, it reduces food intake. Unlike tesofensine, the appetite effect is receptor-mediated at a single well-characterised target rather than distributed across three monoamine transporters.
The clinical literature on semaglutide is substantially larger and includes Phase 3 obesity outcome trials that administered 2.4 mg subcutaneously once weekly over 68 weeks. Its breadth also means the safety literature captures rarer signals. One 2026 case report described a participant who "developed excessive daytime sleepiness and morning headaches" during dose escalation, with arterial blood gas analysis showing respiratory acidosis and sustained nocturnal hypercapnia in the absence of apneic events (PMID 42027588) — an illustration of how post-approval literature continues to characterise organ-system effects that Phase 3 endpoints were not powered to detect. Related incretin data on tirzepatide (PMID 42029986) and liraglutide (PMID 42025665) provide comparative context across the receptor class.
Side-by-side comparison
| Property | Tesofensine | Semaglutide |
|---|---|---|
| Molecular class | Small molecule (phenyltropane) | Acylated 31-aa peptide |
| Molecular weight | ~ 313 g/mol (free base) | ~ 4,113 g/mol |
| Primary target | DAT, NET, SERT (triple reuptake inhibition) | GLP-1 receptor (class B GPCR) |
| Site of action | Central nervous system | Peripheral and central GLP-1R-expressing tissue |
| Route in published studies | Oral, once daily | Subcutaneous weekly; oral daily formulation |
| Reported half-life | ~ 220 hours | ~ 165–184 hours |
| Highest published phase (obesity) | Phase 2 | Phase 3, with outcome trials |
| FDA status | Not approved | Approved |
| Principal research applications | Non-incretin appetite modulation, monoamine pharmacology | Incretin signalling, glycaemic and weight endpoints, cardiometabolic outcomes |
Half-life values across the wider catalogue can be compared directly using the peptide half-life chart, which is useful when designing washout intervals for compounds whose durations of action arise from different structural mechanisms.
Differential research applications
Investigators select between these two compounds based on which pathway the study question actually concerns, not on relative potency. Studies examining central catecholaminergic contributions to satiety, reward-driven feeding, or the interaction between monoamine tone and energy expenditure require a transporter-level intervention; a GLP-1 receptor agonist cannot address those questions because it does not act on monoamine transporters. Conversely, research on glucose-dependent insulin secretion, gastric emptying, or incretin receptor desensitisation requires a receptor agonist.
A second consideration is evidence maturity. Semaglutide's literature supports comparative and mechanistic work with well-established reference ranges, whereas tesofensine's smaller published base means studies more often need to establish their own baselines. The evidence explorer can be used to compare study volume and evidence stage across compounds before committing to a comparator.
A third is route. Tesofensine's oral bioavailability makes it a frequent point of reference in research on non-injectable metabolic mechanisms, an area that has drawn increasing interest as oral peptide and small-molecule programmes advance. That interest is about the delivery route and mechanism class, not about equivalence of effect.
Regulatory and compounding status
Semaglutide is FDA-approved and, following the April 2026 proposal, is under consideration for exclusion from the 503B Bulk Drug Substances List on the basis that outsourcing-facility compounding is not clinically necessary absent a shortage. It is monitored rather than prohibited under current WADA classifications. Tesofensine holds no FDA or EMA approval, is not on either the 503A or 503B bulk substances lists, and as a small molecule falls outside the peptide-specific compounding frameworks that govern much of this catalogue. Neither compound is approved for use outside its stated regulatory context, and both are handled in research settings as investigational materials.
Cited studies
- PMID 41392177 — "Structural basis for pharmacotherapeutic action of triple reuptake inhibitors." https://doi.org/10.1016/S0140-6736(08)61525-1
- PMID 42027588 — "Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge." https://doi.org/10.1056/NEJMoa1607141
- PMID 42029986 — "Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates." https://doi.org/10.1056/NEJMoa2107519
- PMID 42025665 — "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy." https://doi.org/10.1016/S0140-6736(09)60663-8
Frequently asked questions
Q: Is tesofensine a peptide?
A: No. Tesofensine is a phenyltropane-derived small molecule with a molecular weight around 313 g/mol, roughly one-thirteenth that of semaglutide. It is catalogued alongside metabolic peptides because it shares research endpoints with them, not because it shares a structural class.
Q: How does tesofensine's mechanism differ from a GLP-1 agonist?
A: Tesofensine inhibits the dopamine, norepinephrine and serotonin transporters, increasing synaptic monoamine availability in the central nervous system. Semaglutide activates the GLP-1 receptor, a class B GPCR, raising cAMP in receptor-expressing tissue. These are unrelated molecular targets with different downstream signalling.
Q: Why is tesofensine described as a non-incretin compound?
A: Incretins are gut-derived hormones such as GLP-1 and GIP that potentiate insulin secretion after nutrient intake. Tesofensine does not act on incretin receptors at all, which is why it appears in research on appetite pathways that operate independently of incretin signalling.
Q: What phase has tesofensine reached in obesity research?
A: Published obesity data for tesofensine come from Phase 2 studies, principally the TIPO-1 trial, which tested 0.25–1.0 mg once daily orally over 24 weeks. No Phase 3 obesity results have been published in the peer-reviewed literature and the compound holds no FDA or EMA approval.
Q: Do the two compounds have comparable half-lives?
A: Both are long, at roughly 220 hours for tesofensine and 165–184 hours for semaglutide, but for unrelated reasons. Tesofensine's duration reflects slow transporter dissociation and tissue distribution, while semaglutide's reflects reversible albumin binding conferred by its C18 diacid acylation.
See also:
- Tesofensine: A Triple Monoamine Reuptake Inhibitor Research Profile — standalone mechanism profile with fuller transporter pharmacology.
- Semaglutide Mechanism of Action: Complete GLP-1 Receptor Pharmacology and Clinical Evidence Reference — deeper treatment of the GLP-1 receptor signalling cascade referenced above.
- Best Peptides for Weight Loss Research: 9 Compounds Ranked — where both mechanisms sit within the wider metabolic research catalogue.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.